New hope for tough breast cancer: immune therapy trial targets aggressive cases
NCT ID NCT02971748
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard hormone therapy helps prevent cancer from returning in patients with a specific, aggressive type of breast cancer. It is for people whose cancer did not completely disappear after initial chemotherapy and who have completed or are about to start radiation. The goal is to see if boosting the body's immune system can help control the disease longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IIIB BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.